See All Slides - tctmd.com

Slides

Presentation TCT 2012

Relative Frequency and Implication of Periprocedural vs. Spontaneous MI

Presenter: Sripal Bangalore

October 22, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Presenter: Georg Nickenig

October 22, 2012

Presentation TCT 2012

Non-Left Main Bifurcation PCI: Integrated Use of FFR and IVUS

Presenter: Soo-Jin Kang

October 22, 2012

Presentation TCT 2012

Non-Left Main Bifurcation Stenting: Highlights from the Last 12 Months

Presenter: Nick Curzen

October 22, 2012

Presentation TCT 2012

RESPECT: Late Breaking Trial Preview

Presenter: John Carroll

October 22, 2012

Presentation TCT 2012

TCT-108: Performance and Safety of the TRUE Dilatation Balloon Valvuloplasty Catheter for Aortic Balloon Valvuloplasty in Patients Undergoing TAVR

Presenter: Felix Woitek

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

DES Clinical Outcomes Meta-analysis

Presenter: Sripal Bangalore

October 22, 2012

Presentation TCT 2012

The NOBLE Trial: Novel Aspects and Status Update

Presenter: Leif Thuesen

October 22, 2012

Advertisement

Slides

Relative Frequency and Implication of Periprocedural vs. Spontaneous MI

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

AND, Should Also be Based on Hemodynamic Assessments: The Dimensionless AR Index

Non-Left Main Bifurcation PCI: Integrated Use of FFR and IVUS

Non-Left Main Bifurcation Stenting: Highlights from the Last 12 Months

RESPECT: Late Breaking Trial Preview

TCT-108: Performance and Safety of the TRUE Dilatation Balloon Valvuloplasty Catheter for Aortic Balloon Valvuloplasty in Patients Undergoing TAVR

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

DES Clinical Outcomes Meta-analysis

The NOBLE Trial: Novel Aspects and Status Update

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content